Working… Menu

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03976648
Recruitment Status : Terminated (The benefit-risk profile no longer supports continuing the studies)
First Posted : June 6, 2019
Last Update Posted : May 6, 2021
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:
This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Drug: GLPG1690 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Orally Administered GLPG1690 in Subjects With Systemic Sclerosis
Actual Study Start Date : July 18, 2019
Actual Primary Completion Date : April 13, 2021
Actual Study Completion Date : April 13, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma

Arm Intervention/treatment
Experimental: GLPG1690 Drug: GLPG1690
film-coated tablets of GLPG1690 for oral use

Primary Outcome Measures :
  1. Number of adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: From start of study medication in study GLPG1690-CL-204 through day 30 after last dose in study GLPG1690-CL-206 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects who completed the 24-week treatment period of Study GLPG1690-CL-204 and who according to the investigator's judgment may benefit from long-term treatment with GLPG1690.

Exclusion Criteria:

  • Any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03976648

Layout table for location information
United States, California
Pacific Arthritis Care Center
Los Angeles, California, United States, 90045
UCLA Rheumatology
Los Angeles, California, United States, 90095
United States, Florida
RASF Clinical Research Center
Boca Raton, Florida, United States, 33486
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Texas
Metroplex Clinical Research Center
Dallas, Texas, United States, 75231
UT Physicians Center for Autoimmunity
Houston, Texas, United States, 77030
UZ Gent
Gent, Belgium, 9000
UZ Leuven
Leuven, Belgium, 3000
Azienda Ospedaliero Universitaria Careggi
Firenze, Italy, 50139
Ospedale San Raffaele S.r.l. - PPDS
Milano, Italy, 20132
Hospital Universitario Vall d'Hebron
Barcelona, Spain, 8035
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
United Kingdom
University Hospital Aintree
Liverpool, United Kingdom, L9 7AL
Royal Free Hospital
London, United Kingdom, NW32QG
Sponsors and Collaborators
Galapagos NV
Layout table for investigator information
Study Director: Dick de Vries, MD Galapagos NV
Layout table for additonal information
Responsible Party: Galapagos NV Identifier: NCT03976648    
Other Study ID Numbers: GLPG1690-CL-206
2019-001279-34 ( EudraCT Number )
First Posted: June 6, 2019    Key Record Dates
Last Update Posted: May 6, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases